Bristol-Myers Squibb Company (BMY) reported better-than-expected results for the fourth quarter of 2023 on the back of growth in its new product portfolio. The company reported adjusted earnings per share of $1.70, which beat the Zacks Consensus Estimate of $1.52. In the year-ago quarter, BMY posted adjusted earnings of $1.82.Total revenues of $11.5 billion surpassed the Zacks Consensus Estimate of $11.1 billion. Revenues increased 1% from the year-ago period due to higher sales of new product portfolio, as ...

Key TakeawaysBristol Myers Squibb beat profit and sales estimates as the pharmaceutical firm's new drugs drove sales.The company also posted 2024 earnings guidance above analysts' estimates.Shares of Bristol Myers Squibb edged higher in intraday trading Friday, but have lost nearly 40% of their value since hitting an all-time high in December 2022.Bristol Myers Squibb (BMY) shares edged 0.7% higher in intraday trading Friday after posting better-than-expected results and guidance as it benefited from the ad ...

Q4 2023 Results Forward Looking Statements and Non-GAAP Financial Information This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may ...

Bristol-Myer Squibb Company (NYSE:BMY) Q4 2023 Earnings Conference Call February 2, 2024 8:00 AM ET Company Participants Tim Power - VP, IR Chris Boerner - CEO David Elkins - EVP & CFO Sarnit Hirawat - Chief Medical Officer Adam Lenkowsky - Chief Commercialization Officer Conference Call Participants Luisa Hector - Berenberg Chris Schott - JP Morgan Andrew Baum - Citi Seamus Fernandez - Guggenheim Tim Anderson - Wolfe Research Trung Huynh - UBS Geoff Meacham - Bank of America Matt Phipps - William Blair Ste ...

Bristol Myers Squibb (BMY) reported $11.48 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.6%. EPS of $1.70 for the same period compares to $1.82 a year ago.The reported revenue represents a surprise of +3.54% over the Zacks Consensus Estimate of $11.08 billion. With the consensus EPS estimate being $1.52, the EPS surprise was +11.84%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations t ...

Bristol Myers Squibb Co. BMY, -0.41% on Friday reported fourth-quarter results that beat analysts’ expectations, helped by portfolio stalwarts like the blood thinner Eliquis as well as strong growth among newer drugs. The drugmaker reported fourth-quarter net income of $1.762 billion, or 87 cents per share, down from $2.022 billion, or 95 cents per share, in the year-earlier period. Adjusted earnings per share came to $1.70, down 7% from a year earlier but ahead of the FactSet consensus of $1.55. Revenue to ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2023, which reflect strong pipeline acceleration, continued portfolio diversification, and momentum in our business. “ We saw good performance in the fourth quarter from our in-line and new products and took several actions to strengthen the company and build a foundation for sustainable growth,” said Christopher Boerner, Ph.D., chief executive officer, Bristol Myers Squibb. “ In ...

Bristol Myers Squibb Company (BMY) announced that the FDA has accepted its two supplemental biologics license applications (sBLA) seeking label expansion for Breyanzi in two new indications. The sBLAs are seeking approval for Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and relapsed or refractory mantle cell lymphoma (MCL) after a Bruton tyrosine kinase inhibitor (BTKi).Breyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, whic ...

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.It took s ...

BALA CYNWYD, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. AVROBIO, Inc. (Nasdaq – AVRO) Under the terms of the agreement, AVROBIO will merge with Tectonic Therapeutic, Inc. ("Tectonic"). In the deal, pre-Merger AVROBIO shareholders ...